Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma.
convalescent plasma
ebolavirus
ebolavirus infection
epitope mapping
glycoprotein
neutralizing antibodies
proteo-genomics
viral antibodies
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
08
05
2021
accepted:
28
06
2021
entrez:
2
8
2021
pubmed:
3
8
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Three clinically relevant ebolaviruses - Ebola (EBOV), Bundibugyo (BDBV), and Sudan (SUDV) viruses, are responsible for severe disease and occasional deadly outbreaks in Africa. The largest Ebola virus disease (EVD) epidemic to date in 2013-2016 in West Africa highlighted the urgent need for countermeasures, leading to the development and FDA approval of the Ebola virus vaccine rVSV-ZEBOV (Ervebo
Identifiants
pubmed: 34335620
doi: 10.3389/fimmu.2021.706757
pmc: PMC8322977
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Antigens, Viral
0
Membrane Glycoproteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
706757Subventions
Organisme : NCRR NIH HHS
ID : UL1 RR024975
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI109711
Pays : United States
Organisme : NIAID NIH HHS
ID : UC7 AI094660
Pays : United States
Organisme : NIGMS NIH HHS
ID : R44 GM122102
Pays : United States
Organisme : NIAID NIH HHS
ID : R43 AI129082
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI138932
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000445
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI142785
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201400058C
Pays : United States
Informations de copyright
Copyright © 2021 Gilchuk, Guthals, Bonissone, Shaw, Ilinykh, Huang, Bombardi, Liang, Grinyo, Davidson, Chen, Gunn, Alter, Saphire, Doranz, Bukreyev, Zeitlin, Castellana and Crowe.
Déclaration de conflit d'intérêts
SB and NC are employees of Abterra Biosciences. JL, ArG, ED, and BD are employees of Integral Molecular. GA is a founder of Seromyx Systems Inc. LZ is employer and co-owner of Mapp Biopharmaceutical. BD is a shareholder of Integral Molecular. AdG was an employee of Mapp Biopharmaceutical. JC has served as a consultant for Luna Biologics, is a member of the Scientific Advisory Board of Meissa Vaccines and is Founder of IDBiologics. The Crowe laboratory at Vanderbilt University Medical Center has received unrelated sponsored research agreements from Takeda Vaccines, IDBiologics and AstraZeneca. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
N Engl J Med. 2019 Dec 12;381(24):2365-2366
pubmed: 31774948
Nature. 2014 Oct 2;514(7520):47-53
pubmed: 25171469
Immunity. 2018 Aug 21;49(2):363-374.e10
pubmed: 30029854
Nat Biomed Eng. 2020 Nov;4(11):1030-1043
pubmed: 32747832
mBio. 2016 Feb 23;7(1):e02154-15
pubmed: 26908579
Nat Biotechnol. 2012 Nov;30(11):1039-43
pubmed: 23138294
J Virol. 2004 May;78(10):5458-65
pubmed: 15113924
Science. 2016 Mar 4;351(6277):1078-83
pubmed: 26912366
Mol Immunol. 2000 Oct;37(14):837-45
pubmed: 11257305
Immunity. 2021 Apr 13;54(4):815-828.e5
pubmed: 33852832
Science. 2021 Jun 4;372(6546):1108-1112
pubmed: 33947773
J Infect Dis. 2018 Nov 22;218(suppl_5):S612-S626
pubmed: 29860496
Science. 2015 Jul 3;349(6243):88-91
pubmed: 26138979
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2993-8
pubmed: 23382245
J Infect Dis. 1998 Sep;178(3):651-61
pubmed: 9728532
N Engl J Med. 2020 May 7;382(19):1832-1842
pubmed: 32441897
Cell Host Microbe. 2019 Mar 13;25(3):367-376.e5
pubmed: 30795981
Nature. 2011 Aug 24;477(7364):340-3
pubmed: 21866103
Virology. 2005 Feb 5;332(1):20-7
pubmed: 15661137
Cell. 2015 Feb 26;160(5):893-903
pubmed: 25723164
Nature. 2011 Aug 24;477(7364):344-8
pubmed: 21866101
Lancet. 2017 Feb 4;389(10068):505-518
pubmed: 28017403
Cold Spring Harb Protoc. 2011 Jun 01;2011(6):716-25
pubmed: 21632777
Curr Opin Immunol. 2018 Aug;53:196-202
pubmed: 29940415
Cell. 2019 May 30;177(6):1566-1582.e17
pubmed: 31104840
Cell Host Microbe. 2019 Jan 9;25(1):49-58.e5
pubmed: 30629918
Nat Rev Immunol. 2020 Apr;20(4):229-238
pubmed: 31836872
Cell. 2017 May 18;169(5):878-890.e15
pubmed: 28525755
Curr Opin Struct Biol. 2009 Aug;19(4):408-17
pubmed: 19559599
Cell. 2016 Jan 28;164(3):392-405
pubmed: 26806128
Lancet Infect Dis. 2018 Jul;18(7):738-748
pubmed: 29627147
Cell Host Microbe. 2020 Mar 11;27(3):418-427.e4
pubmed: 32059794
Nat Med. 2016 Dec;22(12):1456-1464
pubmed: 27820605
Science. 2005 Jun 10;308(5728):1643-5
pubmed: 15831716
Anal Chem. 2018 Sep 18;90(18):10819-10827
pubmed: 30118589
Immunity. 2020 Feb 18;52(2):388-403.e12
pubmed: 32023489
Nature. 2008 Jul 10;454(7201):177-82
pubmed: 18615077
J Virol. 2015 Nov;89(21):10982-92
pubmed: 26311869
Cell Host Microbe. 2018 Aug 8;24(2):221-233.e5
pubmed: 30092199
Cell Rep. 2021 Apr 13;35(2):108984
pubmed: 33852862
Nat Med. 2019 Oct;25(10):1589-1600
pubmed: 31591605
Cell. 2018 Aug 9;174(4):938-952.e13
pubmed: 30096313
Cell Rep. 2019 Apr 2;27(1):172-186.e7
pubmed: 30943399
Nat Microbiol. 2018 Oct;3(10):1084-1089
pubmed: 30150734
J Virol. 2016 Mar 28;90(8):3890-3901
pubmed: 26819310
Nat Biotechnol. 2012 Mar 25;30(5):447-52
pubmed: 22446692
Immunity. 2019 Jun 18;50(6):1530-1541.e8
pubmed: 31216462
J Virol. 2019 Apr 3;93(8):
pubmed: 30728263
Science. 2016 Mar 18;351(6279):1339-42
pubmed: 26917593
Cell Rep. 2017 Apr 11;19(2):413-424
pubmed: 28402862
PLoS Negl Trop Dis. 2012;6(3):e1575
pubmed: 22448295
Cell. 2017 May 18;169(5):891-904.e15
pubmed: 28525756